Study Summary
This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to enable interpretation of relevant efficacy and safety findings of HEMGENIX.
Want to learn more about this trial?
Request More InfoInterventions
HEMGENIXGENETIC
HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.
Factor IX (FIX)BIOLOGICAL
FIX prophylaxis therapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| American Thrombosis and Hemostasis Network | Rochester | New York | United States |
| Medical University Vienna | Vienna | Austria | |
| Aarhus Universitetshospital | Århus N | Denmark | |
| Centre Hospitalier Universitaire de Brest / CHU Morvan | Brest | France | |
| Centre Régional de Traitement de l'Hémophilie | Nantes | France | |
| CHU Nancy - Hôpital Brabois | Vandœuvre-lès-Nancy | France | |
| Klinik für Angiologie/ Hämostaseologie | Berlin | Germany | |
| University of Clinic Bonn | Bonn | Germany | |
| Klinikum der Johann-Wolfgang Goethe Universitaet | Frankfurt | Germany | |
| Hannover Medical School | Hanover | Germany | |
| Hospital Alvaro Cunqueiro Dr. Manuel Rodriquez-Lopez | Vigo | Spain | |
| University Hospital Bern Inselspital | Bern | Switzerland |